Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
EBS

EBS - Emergent BioSolutions Inc Stock Price, Fair Value and News

$11.70-0.52 (-4.26%)
Market Closed

49/100

EBS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

49/100

EBS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$12.21

Target 3M

$12.02

Target 6M

$12.08

EBS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EBS Price Action

Last 7 days

1.7%

Last 30 days

-4.3%

Last 90 days

-8.9%

Trailing 12 Months

6.2%

EBS RSI Chart

EBS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EBS Valuation

Market Cap

614.5M

Price/Earnings (Trailing)

8.1

Price/Sales (Trailing)

0.78

EV/EBITDA

4.06

Price/Free Cashflow

438.92

EBS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$12.21

Target 3M

$12.02

Target 6M

$12.08

EBS Fundamentals

EBS Revenue

Revenue (TTM)

788.9M

Rev. Growth (Yr)

-21.34%

Rev. Growth (Qtr)

64.02%

EBS Earnings

Earnings (TTM)

75.9M

Earnings Growth (Yr)

-55.4%

Earnings Growth (Qtr)

526.67%

EBS Profitability

EBT Margin

13.42%

Return on Equity

13.03%

Return on Assets

5.2%

Free Cashflow Yield

0.23%

EBS Investor Care

Buy Backs (1Y)

3.07%

Diluted EPS (TTM)

1.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025965.4M851.6M788.9M0
20241.2B1.1B1.1B1.0B
2023977.0M1.1B1.1B1.0B
20221.7B1.6B1.5B1.1B
20211.7B1.7B1.6B1.8B
20201.1B1.3B1.3B1.6B
2019855.2M878.2M1.0B1.1B
2018561.8M681.2M705.5M782.4M
2017502.7M512.3M518.8M560.9M
2016540.1M512.4M496.9M488.8M
2015448.4M457.1M477.5M489.3M
2014323.5M351.4M400.3M450.1M
2013274.7M286.7M309.2M312.7M
2012305.2M287.4M295.2M281.9M
2011257.9M283.9M268.7M273.4M
2010000286.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Emergent BioSolutions Inc

EBS
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
 WEBSITEemergentbiosolutions.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES2500

Emergent BioSolutions Inc Frequently Asked Questions

EBS is the stock ticker symbol of Emergent BioSolutions Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Emergent BioSolutions Inc is 614.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check EBS's fair value in chart for subscribers.

The fair value guage provides a quick view whether EBS is over valued or under valued. Whether Emergent BioSolutions Inc is cheap or expensive depends on the assumptions which impact Emergent BioSolutions Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EBS.

As of Wed Jan 28 2026, EBS's PE ratio (Price to Earnings) is 8.1 and Price to Sales (PS) ratio is 0.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EBS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Emergent BioSolutions Inc has provided -0.108 (multiply by 100 for percentage) rate of return.